OBI presented its Obrion™ ADC technologies at AntibodyChina 2026, highlighting process scale-up, clinical supply feasibility, and GlycOBI DUO® dual-payload design.
🔗 www.obipharma.com/news/antibod...
#OBIPharma #AntibodyChina2026 #ADC #Obrion #GlycOBI #DualPayload #Shanghai
OBI participated in BIO-Europe Spring®, advancing international business development and global partnering efforts.
🔗 obipharma.com/news/bio-eur...
#OBIPharma #ADC #Biotech #Licensing #BIOEurope #DrugDevelopment
Our CEO, Dr. Heidi Wang, was invited to speak at Biologics World Taiwan 2026.
She shared insights on global regulatory strategy and drug development from IND to NDA.
🔗 Read more: lnkd.in/gEJci5TH
#OBIPharma #RegulatoryStrategy #DrugDevelopment #ADC #BWT2026 #BiologicsWorldTaiwan #IMAPAC
🌏 OBI recognized at ABEA 2026 for leadership in ADC innovation
OBI was honored with the title “Best ADC Developer in Taiwan.”
🏆 Dr. Heidi Wang, CEO of OBI, received the Women’s Leadership in ADC Development Award.
#ADCAsiaCongress #ABEA2026 #IMAPAC #OBIPharma
www.obipharma.com/news/obi-is-...
🌍 World ADC London 2026
OBI presented our next-generation bispecific dual-payload ADC strategy at World ADC London 2026.
Our CSO, Dr. Ya-Chi Chen, was invited as a featured speaker and joined a panel on the future of ADCs.
#WorldADC #WorldADCLondon #ADC #OBIPharma
🔗 lnkd.in/g2pDfj3W
🌍 World Cancer Day 2026｜United by Unique🧡
OBI Pharma stands with patients this World Cancer Day.
We join hands with @uiccofficial.bsky.social to honor the theme "United by Unique", which recognizes the diverse journeys of people affected by cancer.
#WorldCancerDay #UnitedByUnique
#OBIPharma #ADC
🚀 OBI Pharma has signed an exclusive global license agreement with TegMine Therapeutics, Inc. for a glycan-targeting ADC.
#OBIPharma #TegMine #ADC #Oncology #GlycOBI #CancerTherapy #Biotech #Partnership
www.accessnewswire.com/newsroom/en/...
💚 陪伴，是溫柔而堅定的力量
浩鼎生技股份有限公司 很榮幸以公益夥伴身分，支持並參與 #HOPE癌症希望基金會 於亞東醫院進行的病房關懷行動
浩鼎相信，企業的社會責任是以同理與行動，與病友與家屬站在一起
www.facebook.com/share/p/19wd...
#OBIPharma #HopeFoundationForCancerCare
#ESG #PatientSupport
Happy Holidays 🎄✨ and best wishes for a wonderful 2026 🌍🎯
Thank you for your continued trust and support 🤝
#OBIPharma #SeasonGreetings #MerryXMas #HappyHolidays #BestWishes #Grateful #Partnership #LookingAhead
🤝浩鼎與美國 TegMine Therapeutics 簽訂受其委託開發之醣蛋白 ADC 全球專屬授權合約
🌏此次國際授權合作，展現以浩鼎 Obrion™ ADC 技術所開發產品的應用前景🚀
#OBIPharma #Obrion #GlycOBI #Glycoprotein #ADC #ExclusiveLicense #GlobalPartnership
www.obipharma.com/zh-hant/news...
OBI held the 2025 Investors’ Meeting, outlining progress in ADC R&D and clinical development, business strategy, and operating efficiency, while advancing next-generation ADC technologies.
#OBIPharma #ADC #Oncology #PrecisionMedicine #InvestorsMeeting
www.obipharma.com/news/obi-inv...
🎉OBI presented new preclinical results for our bispecific ADC OBI-201 at
@sabcs.bsky.social #SABCS2025, led by our CSO Ya-Chi Chen and the R&D team.
#OBIPharma #OBI201 #ADC #BispecificADC #SABCS2025 #BreastCancerResearch #TROP2
www.obipharma.com/news/obi-201...
OBI’s TROP2 ADC OBI-902 has been granted Orphan Drug Designation by the U.S. FDA for the treatment of cholangiocarcinoma, a rare and aggressive cancer with limited treatment options.
#OBIPharma #OBI902 #ADC #OrphanDrugDesignation #Cholangiocarcinoma
www.accessnewswire.com/newsroom/en/...
OBI CSO Dr. Ya-Chi Chen was invited by
Yang Ming Chiao Tung University to deliver a Special Lecture on Biomedicine.
We appreciate NYCU’s Institute of Biopharmaceutical Sciences for the warm invitation
#ADC #OBIPharma #Biotech #DrugDevelopment #YangMingChiaoTungUniversity #cls_nycu
🎀浩鼎志工熱情響應粉紅十月！
🎀OBI Volunteers Shine in Pink October!
浩鼎志工參與 TBCA「點亮雙色粉紅絲帶」活動💗
已連續第十一年投入志工行列，持續以行動支持乳癌防治與病友關懷 💪
#OBIPharma #PinkOctober #BreastCancerAwareness #Volunteer #TBCA #TeamOBI
www.obipharma.com/zh-hant/news...
Convergence 2025: Adapting to change and uncertainty in the regulatory landscape
www.raps.org/news-and-art...
@MichelleMeng, VP and Head of Global Regulatory Sciences at OBI Pharma, was featured in RAPS Regulatory News.
#OBIPharma #RAPSConvergence #RegulatoryAffairs #ConvergenceCommitteemembers
🌕✨ Wishing everyone a joyful Mid-Autumn Festival!
🤝 Celebrate meaningful collaborations
🏠 Enjoy precious time with loved ones
Happy Mid-Autumn Festival! 🌸🥮
#OBIPharma #MidAutumnFestival #MoonFestival #Partnership #Collaboration
Our CEO, Dr. Heidi Wang, joined the #DoseOfReality podcast with Charles Spence, founder of Discera Search.
Listen here:
🎧 Spotify: lnkd.in/gaGmpyci
🎧 Apple Podcast: lnkd.in/gYHvyhv6
🌐 Website: lnkd.in/g-SR7mMf
#PodcastInterview #DisceraSearch #OBIPharma
www.discera-search.com/podcast/losi...
恭賀我們的合作夥伴 深圳 #艾欣达伟医药科技有限公司：
授權 AST-3424（亦稱 OBI-3424）在中國大陸、香港及澳門的權益(研發、註冊、生產及商業化)予浙江 #海正藥業股份有限公司 (Zhejiang Hisun Pharmaceutical)
ascentawits.com/CompanyNews/...
#OBIPharma #Ascentawits #HisunPharma
#AST3424 #OBI3424
OBI Pharma is excited to announce a technology collaboration with AP Biosciences, Inc. to develop a next-generation bispecific Antibody-Drug Conjugate (ADC). 🤝
🔗 Learn more: www.obipharma.com/news/obi-pha...
#OBIPharma #APBiosciences #ADC #GlycOBI #Innovation #Partnership
🚀 OBI Pharma has enrolled the first patient in our Phase 1/2 clinical trial of OBI-902, our first TROP2-targeted ADC built with our proprietary GlycOBI® technology.
🔗 Learn more: www.globenewswire.com/news-release...
#OBIPharma #ADC #ClinicalTrials
#GlycOBI #OBI902 #Phase1 #firstpatientin
At the 2025 Taiwan Society for Immunotherapy of Cancer (TSITC) Summer Meeting,
OBI Pharma CEO Dr. Heidi Wang presented on:
📌Insights from US FDA rejection letters (CRLs)
📌Principles and key considerations in drug development
#OBIPharma #ADCs #TSITC2025 #DrugDevelopment #PrecisionMedicine #OBI902
2025 OBI 桌球趣味競賽🏓
從球拍到湯匙，創意無限的團隊時光
📹 一起感受我們的創意精神與滿滿能量👑
這場趣味競賽中發揮創意、團隊合作，贏得掌聲與笑聲。
#OBIPharma #TeamOBI #LifeAtOBI
#Innovation #BeyondTheLab
#InternalEngagement #WorkplaceCulture
On 7/28, OBI welcomed the 2025 BIO Asia–Taiwan tour at Taipei Bioinnovation Park. Guests toured our Enzyme, CMC, Biology, and QC labs, exploring our ADC research. Thanks to our team for showcasing OBI’s next-gen therapeutics! #OBIPharma #BIOAsiaTaiwan2025 #TBIP #ADC #LabTour #GlycOBI
OBI Pharma at #BIOAsia2025
7/24, our CEO Dr. Heidi Wang moderated two high-impact sessions (A-6 & A-7) at the 2025 Innovation Forum
#GlycOBI #ADC #OBIPharma #DualPayload #InnovationForum #AntibodyConjugates #InnovationLeadership #Biotech #BIOAsia2025
【BIO Asia–Taiwan 2025｜the Investment Summit】
Today (7/23), our CEO Dr. Heidi Wang joined the Investment Summit on the 7th floor of the TaiNEX2, delivering OBI Pharma’s roadshow presentation.
#BIOAsiaTaiwan2025
#OBIPharma #ADC #GlycOBI #PrecisionMedicine #InvestmentSummit
【BIO Asia–Taiwan 2025｜OBI & OBIGEN 】
📍7/23 13:50–15:10｜OBI Roadshow
📍7/23 17:20–17:55｜OBIGEN Roadshow
📍7/24 14:40–15:05｜Innovation Forum Talk
📍7/24 16:30–17:10｜Panel Discussion
#OBIPharma #BIOAsiaTaiwan2025 #ADC #OBIGEN #PrecisionMedicine
www.obipharma.com/news/obi-pha...
🌟 [OBI Training Program] Soft Skills and Leadership Series – Cultivate Leadership Presence 🌟
(7/14) OBI Pharma CEO Dr. Heidi Wang led an insightful session on cultivating leadership presence.
#LeadershipPresence #SoftSkills #LeadershipDevelopment #OBIPharma #TID
🔬 2025 Annual General Meeting｜Strategy, Innovation, and Out-Licensing
At our 2025 AGM, OBI Pharma reaffirmed its strategic focus on Antibody-Drug Conjugates (ADCs).
#ADC #OBIPharma #AGM2025 #PrecisionMedicine #DrugDevelopment #Obrion
www.obipharma.com/news/innovat...
OBI Pharma showcased its next-gen #ADC strategies at #2025WorldADCAsia with 3 talks, 1 panel & 3 posters!
#OBIPharma #NextGenADC #Oncology #DualPayload #TargetedTherapy #WorldADCEventSeries
www.obipharma.com/news/2025-wo...
